Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS

Mohamed Sayed Abdelhafez300 enrolled

Overview

The purpose of this study is to evaluate the effect of administration of low dose of human chorionic gonadotropin (HCG) after use of clomiphene citrate (CC) for induction of ovulation in infertile women having CC resistant polycystic ovarian syndrome (PCOS).

Women will be randomly divided into two groups; CC-HCG group and CC group. Women in the CC-HCG group will receive CC (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle). Women in the CC group will receive CC alone (150 mg/day for 5 consecutive days from day 2 of cycle). Transvaginal sonography (TVS) scan will be performed regularly for monitoring of follicular growth (folliculometry); starting from day 10 of the stimulation cycle and repeated every 2-3 days. When there will be at least one follicle ≥ 18 mm in diameter, final oocyte maturation will be induced by intramuscular administration of 10000 IU of HCG and timed intercourse will be advised. If there will be no follicle ≥ 12 mm by day 16 of the cycle, monitoring of follicular growth will be discontinued and the cycle will be presumed to be anovulatory. Ovulation will be documented by TVS scan one week after triggering of oocyte maturation and will be confirmed by assessing the midluteal serum progesterone level. Each woman will be subjected to ovarian stimulation for a maximum of 3 consecutive cycles except if she gets pregnant in the first or second cycle

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

300

Conditions

Infertility Polycystic Ovarian Syndrome

Interventions

Clomiphene citrate and Human chorionic gonadotropin (HCG)DRUG

Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)

Clomiphene citrateDRUG

Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Infertile lean women with PCOS as defined by the Rotterdam criteria. * CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles). Exclusion Criteria: * Age \< 20 or \> 35 years. * Presence of any infertility factor other than anovulatory PCOS. * Previous history of ovarian surgery or surgical removal of one ovary. * Previous exposure to cytotoxic drugs or pelvic irradiation. * Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months. * Metabolic or hormonal abnormalities.

Locations (1)

Obstetrics and Gynecology Department in Mansoura University Hospital

Al Mansurah, Egypt

Outcomes

Primary Outcomes

Ovulation rate

Number of ovulatory cycles divided by the number of stimulation cycles

Time frame: 3 months

Secondary Outcomes

Number of ovarian follicles ≥ 18 mm on day of triggering of oocyte maturation

Number of ovarian follicles ≥ 18 mm by TVS on day of triggering of oocyte maturation

Time frame: 3 months

Endometrial thickness on day of triggering of oocyte maturation

Endometrial thickness by Transvaginal sonography (TVS) scan on day of triggering of oocyte maturation

Time frame: 3 months

Clinical pregnancy rate

Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women

Time frame: 6-8 weeks gestational age

Incidence of early ovarian hyperstimulation syndrome (OHSS)

Incidence of OHSS within 9 days of final triggering of oocyte maturation

Time frame: Within 9 days of final triggering of oocyte maturation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.